Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer
| Autor: | Yutaka Arai, Chul Jang Kim, Hiroki Soga, Keita Takimoto, Takashi Osafune, Akihiro Kawauchi, Tokuhiro Chano, Shigehisa Kubota, Yuji Sakano, Susumu Kageyama, Koki Maeda, Zenkai Nishikawa, Tetsuya Yoshida |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Pirarubicin Urology pirarubicin General Biochemistry Genetics and Molecular Biology medicine Clinical endpoint Humans Adverse effect Pharmacology Bladder cancer Tumor size business.industry medicine.disease Immediate postoperative single instillation Administration Intravesical Urinary Bladder Neoplasms Doxorubicin Neoplasm Recurrence Local Non muscle invasive business Intravesical chemotherapy non-muscle-invasive bladder cancer Retention time Research Article medicine.drug |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| Popis: | Background:This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer. Patients and methods:We analyzed 165 patients with low-risk non-muscle-invasive bladder cancer who underwent transurethral surgery. Single instillation of pirarubicin with 15-min retention time immediate after surgery was performed in 47 (28%) patients. The other patients (118, 72%) were treated without instillation therapy. The primary endpoint was recurrence-free survival. Results:Median overall follow-up was 50 (range=6-134) months. Recurrence-free survival at 1 and 5 years was 91% and 72%, and 79% and 54% in the group treated with pirarubicin, and that treated with surgery alone, respectively (p=0.031). Cox's hazard analysis revealed lack of instillation and larger tumor size (>10 mm) as significant factors for risk of recurrence. No adverse events regarding intravesical chemotherapy were observed. Conclusion:Pirarubicin instillation with 15-min retention time can prevent intravesical recurrence of low-risk bladder tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|